Jaguar Health Stock News

During the last session, Jaguar Health Inc. (NASDAQ:JAGX)’s traded shares were 1.44 million, with the beta value of the company hitting 1.52. At the end of the trading day, the stock’s price was $0.60, reflecting an intraday loss of -4.88% or -$0.03. The 52-week high for the JAGX share is $10.02, that puts it down … Is Jaguar Health Inc. (NASDAQ: JAGX) Still A Buy After A -18.10% Weekly Drop? Read More »

In December of 2021, FDA conditionally approved Canalevia ™ -CA1 for treatment of chemotherapy-induced diarrhea in dogs, and the company expects Canalevia could receive FDA conditional approval, under the name Canalevia ™ -CA2, for treatment of EID in dogs SAN FRANCISCO, CA / ACCESSWIRE / February

Jaguar Health <> said it completed filing of a final major regulatory section with the U.S

Canalevia ™ would be first and only FDA-approved plant-based medicine for working dogs that suffer from diarrhea SAN FRANCISCO, CA / ACCESSWIRE / February 10, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that it has

Jaguar Health plans to launch educational and awareness-building activities aimed at dog owners about canine cancer and options for treating side effects of cancer therapy in dogs.

Check these three under $1 penny stocks out for your watchlist The post 3 Penny Stocks to Watch Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com

Check these three under $1 penny stocks out for your watchlist The post 3 Penny Stocks to Watch Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

NEW YORK , Jan. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JAGX, EVFM, ADVM, FREY, and PL. Full story available on Benzinga.com

Jaguar Health Inc (NASDAQ:JAGX) shares are trading higher following a Tuesday 13G filing from Oasis Capital showing a 9.99% stake in the company. According to the filing, Oasis Capital has a passive

Jaguar Health Inc (JAGX) shares closed today at 1.6% above its 52 week low of $0.92, giving the company a market cap of $43M. The stock is currently down 10.1% year-to-date, down 92.2% over the past 12 months, and down 100.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 79.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 224.1% The company's stock price performance over the past 12 months lags the peer average by 302.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Jaguar Health Inc (JAGX) shares closed today at 1.6% above its 52 week low of $0.92, giving the company a market cap of $43M. The stock is currently down 8.5% year-to-date, down 84.2% over the past 12 months, and down 100.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.7%. Trading Activity Trading volume this week was 79.9% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 6.7% lower than its 5-day moving average, 15.8% lower than its 20-day moving average, and 48.9% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 106.2% The company's stock price performance over the past 12 months lags the peer average by 237.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Jaguar Health, Inc. (NASDAQ:JAGX) saw unusually large options trading activity on Tuesday. Traders acquired 9,504 call options on the stock. This represents an increase of 1,059% compared to the average volume of 820 call options. NASDAQ:JAGX opened at $1.18 on Thursday. Jaguar Health has a fifty-two week low of $1.05 and a fifty-two week high [] The post Jaguar Health Target of Unusually Large Options Trading (NASDAQ:JAGX) appeared first on ETF Daily News .

NEW YORK , Dec. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SEAC, ALLK, PTPI, OSCR, and JAGX. Full story available on Benzinga.com

By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar''s novel, oral plant-based product sustainably harvested from the Croton lechleri treeSAN FRANCISCO, CA / A

(PR-inside.com) By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar''s novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA / ACCESSWIRE / December 22, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today shared the following quote from the press release the U.S. Food and Drug Administration (FDA) issued December 21, 2021: "Diarrhea is a common side effect of chemotherapy in dogs, which can be so severe that cancer treatment must be halted. Chemotherapy drugs often have potential side effects, but, unlike in human medicine where patients may be willing to tolerate some discomfort in exchange for ..